Literature DB >> 15383024

Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.

Lily Lin1, Roberta Dikeman, Barbara Molini, Sheila A Lukehart, Robert Lane, Kent Dupuis, Peyton Metzel, Laurence Corash.   

Abstract

BACKGROUND: Bacterial contamination of platelet (PLT) concentrates can result in transfusion-transmitted sepsis. A photochemical treatment (PCT) process with amotosalen HCl and long-wavelength ultraviolet light (UVA), which cross-links nucleic acids, was developed to inactivate bacteria and other pathogens in PLT concentrates. STUDY DESIGN AND METHODS: High titers of pathogenic aerobic and anaerobic Gram-positive bacteria (10 species), aerobic Gram-negative bacteria (7 species), and spirochetes (2 species) were added to single-donor PLT concentrates containing 3.0 x 10(11) to 6.0 x 10(11) PLTs in approximately 300 mL of 35 percent plasma and 65 percent PLT additive solution (InterSol, Baxter Healthcare) or saline. After PCT with 150 micro mol per L amotosalen and 3 J per cm(2) UVA, residual bacterial levels were detected by sensitive microbiologic methods.
RESULTS: The level of inactivation of viable bacteria was expressed as log reduction. Log reduction of Gram-positive bacteria for Staphylococcus epidermidis was > 6.6; for Staphylococcus aureus, 6.6; for Streptococcus pyogenes, > 6.8; for Listeria monocytogenes, > 6.3; for Corynebacterium minutissimum, > 6.3; for Bacillus cereus (vegetative), > 5.5; for Lactobacillus sp., > 6.4; for Bifidobacterium adolescentis, > 6.0; for Propionibacterium acnes, > 6.2; and for Clostridium perfringens, > 6.5. Log reduction of Gram-negative bacteria for Escherichia coli was > 6.4; for Serratia marcescens, > 6.7; for Klebsiella pneumoniae, > 5.6; for Pseudomonas aeruginosa, 4.5; for Salmonella choleraesuis, > 6.2; for Yersinia enterocolitica, > 5.9; and for Enterobacter cloacae, 5.9. Log reduction of spirochetes for Treponema pallidum was 6.8 to 7.0, and for Borrelia burgdorferi, > 6.9.
CONCLUSION: PCT inactivates high levels of a broad spectrum of pathogenic bacteria. The inactivation of bacteria in PLT concentrates offers the potential to prospectively prevent PLT-transfusion-associated bacteremia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383024     DOI: 10.1111/j.1537-2995.2004.04125.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  25 in total

1.  Laboratory Evaluation of the Effectiveness of Pathogen Reduction Procedures for Bacteria.

Authors:  Thomas H Müller; Thomas Montag; Axel W Seltsam
Journal:  Transfus Med Hemother       Date:  2011-07-08       Impact factor: 3.747

Review 2.  Economics of pathogen inactivation technology for platelet concentrates in Japan.

Authors:  Ulf Staginnus; Laurence Corash
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

3.  Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™

Authors:  Johannes Irsch; Lily Lin
Journal:  Transfus Med Hemother       Date:  2011-01-27       Impact factor: 3.747

4.  Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates.

Authors:  Reinhard Henschler; Erhard Seifried; Nina Mufti
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

5.  In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step.

Authors:  Mélanie Abonnenc; Giona Sonego; Julie Kaiser-Guignard; David Crettaz; Michel Prudent; Jean-Daniel Tissot; Niels Lion
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

6.  Transfusion-related Listeria monocytogenes infection in a patient with acute myeloid leukaemia.

Authors:  Giulia Tolomelli; Pier Luigi Tazzari; Michela Paolucci; Mario Arpinati; Maria P Landini; Pasqualepaolo Pagliaro
Journal:  Blood Transfus       Date:  2014-06-05       Impact factor: 3.443

Review 7.  Pathogen-reduced platelets for the prevention of bleeding.

Authors:  Lise J Estcourt; Reem Malouf; Sally Hopewell; Marialena Trivella; Carolyn Doree; Simon J Stanworth; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2017-07-30

8.  Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.

Authors:  Dragoslav Domanović; Ines Ushiro-Lumb; Veerle Compernolle; Sergio Brusin; Markus Funk; Pierre Gallian; Jørgen Georgsen; Mart Janssen; Teresa Jimenez-Marco; Folke Knutson; Giancarlo M Liumbruno; Polonca Mali; Giuseppe Marano; Yuyun Maryuningsih; Christoph Niederhauser; Constantina Politis; Simonetta Pupella; Guy Rautmann; Karmin Saadat; Imad Sandid; Ana P Sousa; Stefania Vaglio; Claudio Velati; Nicole Verdun; Miguel Vesga; Paolo Rebulla
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

9.  Photochemical inactivation of chikungunya virus in human apheresis platelet components by amotosalen and UVA light.

Authors:  Konstantin A Tsetsarkin; Adam Sampson-Johannes; Lynette Sawyer; John Kinsey; Stephen Higgs; Dana L Vanlandingham
Journal:  Am J Trop Med Hyg       Date:  2013-03-25       Impact factor: 2.345

10.  Preparation and pathogen inactivation of double dose buffy coat platelet products using the INTERCEPT blood system.

Authors:  Mohammad R Abedi; Ann-Charlotte Doverud
Journal:  J Vis Exp       Date:  2012-12-07       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.